9 recruiting, 3 completed, 2 active not recruiting, 1 terminated. 8 Phase 2, 3 Phase 1, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Stage IVA Laryngeal Cancer AJCC v8: new trials by email Literature Review of Stage IVA Laryngeal Cancer AJCC v8 trials Research Report on Stage IVA Laryngeal Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma Biospecimen Collection, Camonsertib, Computed Tomography - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 39 | 2027-02-13 | 2026-09-03 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-08-17 |
| Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Biopsy Procedure, Biospecimen Collection - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 44 | 2026-05-27 | 2026-10-16 |
| Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer Biospecimen Collection, Carboplatin, Cemiplimab - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 180 | 2026-04-24 | 2026-10-14 |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer Best Practice, Biospecimen Collection, Cisplatin - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Recruiting | NRG Oncology | 98 | 2025-06-23 | 2026-08-17 |
| Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer Computed Tomography, Fludeoxyglucose F-18, Intensity-Modulated Proton Therapy - Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Early Phase 1 | Recruiting | Emory University | 20 | 2024-12-03 | 2025-10-22 |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Biopsy Procedure, Biospecimen Collection, Cisplatin - Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 46 | 2022-09-19 | 2026-09-22 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Carboplatin, Cemiplimab, Paclitaxel - Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Marcelo Bonomi | 46 | 2021-11-30 | 2026-06-25 |
| Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer Treatment Medical Device Usage and Evaluation, Consultation, Exercise Intervention - Head and Neck Carcinoma, Hypopharyngeal Carcinoma | Not applicable | Completed | Thomas Jefferson University | 12 | 2021-03-28 | 2025-05-22 |
| Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Cisplatin, Hearing Handicap Inventory for Adults - Screening, Radiation Therapy - Clinical Stage III Human Papillomavirus (HPV)-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Completed | Hyunseok Kang, MD | 16 | 2020-10-14 | 2024-06-28 |
| Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer Celecoxib, Placebo, Quality-of-Life Assessment - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 2 | Terminated | University of Utah | 13 | 2019-11-27 | 2025-02-12 |
| Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Cetuximab, Durvalumab, Intensity-Modulated Radiation Therapy - Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 196 | 2018-04-03 | 2026-08-27 |
| Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer Biospecimen Collection, Questionnaire Administration - Carcinoma of Unknown Primary, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Recruiting | M.D. Anderson Cancer Center | 471 | 2016-12-29 | 2026-10-06 | |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis - Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | ECOG-ACRIN Cancer Research Group | 189 | 2016-11-23 | 2026-09-14 |
Laryngeal Neoplasms (15) · Carcinoma (13) · Hypopharyngeal Neoplasms (13) · Mouth Neoplasms (13) · Oropharyngeal Neoplasms (13) · Squamous Cell Carcinoma of Head and Neck (8) · Nasopharyngeal Carcinoma (3) · Paranasal Sinus Neoplasms (2) · Lung Neoplasms (1) · Lymphoid Interstitial Pneumonia (1) · Maxillary Sinus Neoplasms (1) · Neoplasms, Unknown Primary (1) · Stomatitis (1)
Head and Neck Neoplasms (15) · Laryngeal Diseases (15) · Neoplasms (15) · Neoplasms by Site (15) · Otorhinolaryngologic Diseases (15) · Otorhinolaryngologic Neoplasms (15) · Pharyngeal Diseases (15) · Pharyngeal Neoplasms (15) · Respiratory Tract Diseases (15) · Respiratory Tract Neoplasms (15) · Stomatognathic Diseases (15) · Neoplasms by Histologic Type (14) · Neoplasms, Glandular and Epithelial (14) · Mouth Diseases (13) · Carcinoma, Squamous Cell (8)
Magnetic Resonance Spectroscopy (7) · Radiotherapy, Intensity-Modulated (6) · Specimen Handling (6) · 1,2-diaminocyclohexaneplatinum II citrate (5) · Cisplatin (5) · Platinum (4) · Carboplatin (3) · Paclitaxel (3) · Radiation (3) · Radiotherapy (3) · Taxes (3) · cemiplimab (3) · (225)Ac-DOTA-c(RGDyK) (2) · Biopsy (2) · Cetuximab (2)
National Cancer Institute (NCI) (6) · NRG Oncology (2) · ECOG-ACRIN Cancer Research Group (1) · Emory University (1) · Hyunseok Kang, MD (1) · M.D. Anderson Cancer Center (1) · Marcelo Bonomi (1) · Thomas Jefferson University (1) · University of Utah (1)
United States (15) · Canada (2)
Loren K Mell (2) · Amol M Takalkar, MD, MS, MBA, FACNM (1) · David M Brizel (1) · Eileen H Shinn (1) · Hyunseok Kang, MD (1) · Malcolm D Mattes (1) · Marcelo R Bonomi, MD (1) · Matin Imanguli (1) · Maura L Gillison (1) · Nabil F Saba (1) · Richard Cannon, MD (1) · Robert Ferris (1) · Yvonne M Mowery (1)
U10CA180868 (4), P30CA042014 (1), P30CA138292 (1), R21DE019954 (1), U10CA180820 (1), UG1CA189867 (1), UM1CA186644 (1), UM1CA186690 (1), UM1CA186691 (1)